Lamotrigine (Epilepsy)

Study	Exclusion reasons	Rmk	Reference
Husebye (Lamotrigine) (Controls unexposed, sick), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Husebye (Lamotrigine) (Controls unexposed, disease free), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Elkjaer, 2018	repeat population groups, duplicate reports (most recent study included)	Overlapping: this publication totally included the data of Elkjaer, 2018, for an higher academic grade => use of Ren 2023.	Elkjaer JAMA Neurol 2018; 75:663-671 10.1001/jamaneurol.2017.5035
Meador, 2021	repeat population groups, duplicate reports (most recent study included)	Overlapping: Meador 2021 and 2023 used the same cohort in order to study the same outcome, at 2 different ages (=> use of the data on the older children, i.e Meador 2023).	Meador JAMA Neurol 2021; 78:927-936 10.1001/jamaneurol.2021.1583